Author

Zhiling Liang

Observed name: Zi-Qian Liang

Institutions: Shanxi Medical University, Guangdong Pharmaceutical University, First Affiliated Hospital of Guangdong Pharmaceutical University

Observed institutions: Shanxi Medical University, Guangdong Pharmaceutical University, First Affiliated Hospital of Guangdong Pharmaceutical University

ORCID: 0009-0009-7480-3379

Observed ORCID: 0009-0009-7480-3379

OpenAlex ID: A5059339086

Discovery of Highly Potent, Selective, and Liver-Targeting HSD17B13 Inhibitor with Robust In Vivo Anti-MASH Activity

2025 · Lianru Chen, Zhiling Liang, et al. · Journal of Medicinal Chemistry · 10

Discovery of the First-In-Class HSD17B13/PPAR Multitarget Modulators for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis

2025 · Zhiling Liang, Lianru Chen, et al. · Journal of Medicinal Chemistry · 3

Discovery of P11–2: A Potent First-in-Class MNK1-Targeting PROTAC Degrader for the Treatment of Cancer

2025 · Zhongcheng Yang, Yuxia Liu, et al. · Journal of Medicinal Chemistry · 3

Discovery of Highly Potent and Orally Available CCNK Molecular Glue Degraders as Broad-Spectrum Antitumor Agents

2025 · Yuxia Liu, Zhongcheng Yang, et al. · Journal of Medicinal Chemistry · 2

Association of Th17/Treg immune imbalance and cardiovascular complications in RA patients: retrospective cohort study in refractory subgroups

2025 · Qin-Yi Su, Meng-Yuan Wang, et al. · Clinical Rheumatology · 1

Sotagliflozin: a dual SGLT1/2 inhibitor, for full range of heart failure

2025 · Zheng Li, Zhiling Liang · Elsevier eBooks

Design, synthesis, and biological evaluation of novel highly selective non-carboxylic acid FABP1 inhibitors

2024 · Lianru Chen, Bin Wang, et al. · European Journal of Medicinal Chemistry

Works count: 7

Citation count: 19

H-index: 3

I10-index: 1